@article{oai:niigata-u.repo.nii.ac.jp:00018429,
 author = {高久, 史麿},
 issue = {9-10},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Oct},
 note = {Gene therapy is defined as a procedure to introduce genes or gene-transduced cells into our body with the purpose of treatment of diseases. Gene therapy had started in USA in 1989, and at this moment, more 100 protocols have been approved by the Recombinant DNA advisory committee in NIH, and about 600 patients have been subjected to the clinical trial of these gene therapies. Although the efficacy of gene therapies is not clear in most of them, some gene therapies such as therapy for congenital deficiency of ADA has been reported to be very effective. In our country, the guide line for gene therapy was made by Ministry of Health and Welfare (MHW) in 1993, and the members of Central Committee to evaluate the protocol of gene therapy were appointed by MHW in 1994. The first gene therapy in our country had been started by the pediatricians in Hokkaido University on a boy with a congenital ADA deficiency in August 1995, with vectors supplied from GTI company in USA. To promote the gene therapy in Japan, it is necessary to encourage companies to join the business of making new vectors for gene therapy and to establish the system to evaluate the efficacy and safety of these vectors.},
 pages = {413--417},
 title = {遺伝子治療 : 現状と将来},
 volume = {109},
 year = {1995}
}